Entera Bio/$ENTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Entera Bio
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Ticker
$ENTX
Sector
Primary listing
Employees
20
Headquarters
Jerusalem, Israel
Website
Entera Bio Metrics
BasicAdvanced
$89M
-
-$0.25
1.52
-
Price and volume
Market cap
$89M
Beta
1.52
52-week high
$2.58
52-week low
$1.50
Average daily volume
209K
Financial strength
Current ratio
10.472
Quick ratio
5.888
Long term debt to equity
0.052
Total debt to equity
1.176
Profitability
EBITDA (TTM)
-10.552
Net profit margin (TTM)
-6,386.75%
Operating margin (TTM)
-6,378.92%
Effective tax rate (TTM)
-0.13%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-44.56%
Return on equity (TTM)
-82.22%
Valuation
Price to revenue (TTM)
488.173
Price to book
4.37
Price to tangible book (TTM)
4.37
Price to free cash flow (TTM)
-12.101
Free cash flow yield (TTM)
-8.26%
Free cash flow per share (TTM)
-0.16
Growth
Revenue change (TTM)
191.23%
Earnings per share change (TTM)
-1.69%
3-year revenue growth (CAGR)
-26.44%
3-year earnings per share growth (CAGR)
-19.96%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Entera Bio stock?
Entera Bio (ENTX) has a market cap of $89M as of August 26, 2025.
What is the P/E ratio for Entera Bio stock?
The price to earnings (P/E) ratio for Entera Bio (ENTX) stock is 0 as of August 26, 2025.
Does Entera Bio stock pay dividends?
No, Entera Bio (ENTX) stock does not pay dividends to its shareholders as of August 26, 2025.
When is the next Entera Bio dividend payment date?
Entera Bio (ENTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Entera Bio?
Entera Bio (ENTX) has a beta rating of 1.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.